Format

Send to

Choose Destination
Clin Breast Cancer. 2018 Jun;18(3):e267-e270. doi: 10.1016/j.clbc.2017.11.017. Epub 2017 Nov 28.

Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.

Author information

1
Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
2
Department of Pathology, Rabin Medical Center, Petah Tikva, Israel.
3
Loxo Oncology Inc, South San Francisco, CA.
4
Foundation Medicine, Cambridge, MA.
5
Sorokoa Cancer Institute, Ben Gurion University, Beer-Sheva, Israel. Electronic address: peled.nir@gmail.com.

KEYWORDS:

NGS; NTRK3; SBC; TNBC; Targeted therapy

PMID:
29233640
DOI:
10.1016/j.clbc.2017.11.017

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center